Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Journal Articles Dermatology and Therapy Year : 2022

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study

Domains

Life Sciences [q-bio]

Hélène BILLARD  : Connect in order to contact the contributor

https://hal.inrae.fr/hal-04076820

Submitted on : Friday, April 21, 2023-9:47:56 AM

Last modification on : Wednesday, June 5, 2024-11:08:04 AM

Consult the full text

Dates and versions

hal-04076820 , version 1 (21-04-2023)

Identifiers

Cite

Andrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, Weily Soong, Sebastien Barbarot, et al.. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study. Dermatology and Therapy, 2022, 12 (3), pp.771-785. ⟨10.1007/s13555-022-00694-1⟩. ⟨hal-04076820⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INRAE PHAN NANTES-UNIVERSITE UFR-MEDECINE-NANTES
10 View
0 Download

Altmetric

Share

More